Quoin Pharmaceuticals, Ltd.
QNRX
$5.91
-$0.16-2.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.49M | 6.42M | 6.13M | 5.94M | 5.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.29M | 14.18M | 12.68M | 11.03M | 9.53M |
| Operating Income | -16.29M | -14.18M | -12.68M | -11.03M | -9.53M |
| Income Before Tax | -15.80M | -13.77M | -12.17M | -10.45M | -8.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.80 | -13.77 | -12.17 | -10.45 | -8.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.80M | -13.77M | -12.17M | -10.45M | -8.96M |
| EBIT | -16.29M | -14.18M | -12.68M | -11.03M | -9.53M |
| EBITDA | -16.19M | -14.08M | -12.58M | -10.93M | -9.43M |
| EPS Basic | -743.46 | -1.14K | -1.47K | -1.73K | -2.86K |
| Normalized Basic EPS | -13.28 | -20.30 | -26.28 | -30.91 | -51.05 |
| EPS Diluted | -744.28 | -1.14K | -1.48K | -1.74K | -2.86K |
| Normalized Diluted EPS | -13.28 | -20.30 | -26.28 | -30.91 | -51.05 |
| Average Basic Shares Outstanding | 4.26M | 1.94M | 1.50M | 1.05M | 526.80K |
| Average Diluted Shares Outstanding | 121.50K | 55.30K | 42.60K | 29.90K | 14.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |